The importance of histology and cytogenetics in decision making for renal cell carcinoma

World Journal of Urology

Volumn 26, Issue 2, 2008, Pages 155-160

  Garcia, Julia G ^a   Picken, Maria M ^a   Flanigan, Robert C ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cytogenetics; Histology; Renal cell carcinoma

Indexed keywords

ARTICLE; BIOPSY; CYTOGENETICS; GENETICS; HUMAN; KIDNEY; KIDNEY CARCINOMA; KIDNEY TUMOR; PATHOLOGY; PROGNOSIS;

BIOPSY; CARCINOMA, RENAL CELL; CYTOGENETICS; HUMANS; KIDNEY; KIDNEY NEOPLASMS; PROGNOSIS;

EID: 42349108073     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-008-0262-3     Document Type: Article

References (78)

1. Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics. CA Cancer J Clin 49:8-31
2. Pantuck AJ, Zisman A, Belldegrun AS (2001b) The changing natural history of renal cell carcinoma. J Urol 166:1611-1623
3. Thrasher JB, Paulson DF (1993) Prognostic factors in renal cancer. Urol Clin North Am 20:247-262
4. Delahunt B (1998) Histopathologic prognostic indicators for renal cell carcinoma. Semin Diagn Pathol 15:68-76
5. Kontak JA, Campbell SC (2003) Prognostic factors in renal cell carcinoma. Urol Clin North Am 30:467-80
6. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML (2003) Comparison of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27:612-24
7. Patard JJ, Leray E, Rioux-Leclercq N et al (2005) Prognostic value of histologic subtypes in renal cell carcinoma; a multicenter experience. J Clin Oncol 23:2763-2771
8. Delahunt B, Eble JN, McCredie M, Bethwaite PB, Stewart JH, Bilous AM (2001) Morphologic typing of papillary renal cell carcinoma: Comparison of growth kinetics, patient survival in 66 cases. Hum Pathol 32:590-594
9. Mejean A, Oudard S, Thiounn N (2003) Prognostic factors of renal cell carcinoma. J Urol 169:821-827
10. Chao D, Zisman A, Pantuck AJ et al (2002) Collecting duct carcinoma: clinical study of a rare tumor. J Urol 167:71-74
11. Furhman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655-663
12. Vira MA, Novakovic KR, Pinto PA, Linehan WM (2007) Genetic basis of kidney cancer: A model for developing molecular-targeted therapies. BJU Int 99:1223-1229
13. Linehan WM, Walther MM, Zba B (2003) The genetic basis of cancer of the kidney. J Urol 170:2163-2172
14. Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS (2007) The role of molecular markers in the staging of renal cell carcinoma. BJU Int 99:1208-1211
15. Yang XJ, Sugimura J, Schafernak KT et al (2006) Classification of renal neoplasms based on molecular signatures. J Urol 175:2302-2306
16. Iliopoulos O (2007) Molecular biology of renal cell cancer and the identification of therapeutic targets. J Clin Oncol 24:5593-5600
17. Knight DA, Stadler WM (2007) Prognostic factors in localized renal cell cancer. BJU Int 99:1212-1216
18. AJCC Cancer staging manual, 6th edn (2002)
19. Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H (2005) Independent validation of the 2002 American joint committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 173:1235-1239
20. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKiernion JB, Belldegrun A (2000) Prognostic indicators for renal cell carcinoma: A multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 163:109051095
21. Han K, Bui MHT, Pantuck AJ, Freitas BC et al (2003) TNM T3a renal cell carcinoma: Adrenal gland involvement is not the same as renal fat invasion. J Urol 169:899-904
22. Siemer S, Lehmann J, Loch A, Becker F et al (2005) Current TNM classification of renal cell carcinoma evaluated: Revising stage T3a. J Urol 173:33-37
23. Thompson RH, Leibovich BC, Cheville JC, Webster WS et al (2005) Is renal sinus fat invasion the same as perinephric fat invasion for T3a renal cell carcinoma? J Urol 174:1218-1221
24. Murphy AM, Gilbert SM, Katz AE, Goluboff ET et al (2005) Re-evaluation of the tumour-node-metastasis staging of locally advanced renal cortical tumours; absolute size (T2) is more significant than renal capsular invasion (T3a). BJU Int 95:27-30
25. Pantuck AJ, Zisman A, Dorey F et al (2003) Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 97:2995-3002
26. Golimbu M, Tessler A, Al-Askari S et al (1986) Renal cell carcinoma: survival and prognostic factors. Urology 27:291-301
27. Herrlinger A, Schrott KM, Schott G, Sigel A (1991) What are the benefits of extended dissection of the regional lymph nodes in the therapy of renal cell carcinoma? J Urol 146:1224-1227
28. Phillips CK, Taneja SS (2004) The role of lymphadenectomy in the surgical management of renal cell carcinoma. Urol Oncol 22:214-224
29. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belegrun AS (2005) Renal cell carcinoma 205: New frontiers in staging, prognostication and targeted molecular therapy. J Urol 173:1853-1862
30. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML (2003) Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27:612-624
31. Beck SD, Patel MI, Snyder ME et al (2004) Effects of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 11:71-77
32. Childs R, Chenroff A, Cotentin N et al (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Eng J Med 343:750-758
33. Drachenberg D, Childs R (2003) Allogeneic hematopoetic stem cell transplantation for cytokine refractory renal cell carcinoma. Cancer Treat Res 116:213-226
34. Vogelzang NJ, Sternber CN (2007) Signal-transduction inhibitors in renal cell carcinoma. BJU Int 99:1289-1295
35. Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB (2005) Histlogical predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 28:488-495
36. Pattard JJ, Leray E, Rioux-Leclercq N et al (2005) Prognostic value of histologic subtypes in renal cell carcinoma: A multicenter experience. J Clin Oncol 23:2763-2771
37. Oyasu R (1998) Renal cancer: Histologic classification update. Int J Clin Oncol 3:125-133
38. Brunelli M, Eble Jn, Zhang S et al (2003b) Gains of chromosome 7, 17, 12, 16 and 20 and loss of Y occur early in the evolution of papillary renal cell neoplasia: A fluorescent in situ hybridization study. Mod Pathol 16:1053-1059
39. Kuroda N, Toi M, Hiroi M et al (2003a) Review of chromophobe renal cell carcinoma with focus on clinical and pathobiological aspects. Histopathol 18:165-171
40. Pavlovich CP, Schmidt LS (2004) Searching for the hereditary causes of renal cell carcinoma. Nat Rev 4:381-393
41. Fuzesi L, Cober LM, Mittermayer CH (1992) Collecting duct carcinoma: cytogenetic characterization. Histopathol 21:155-160
42. Steiner G, Cairns P, Polascik TJ et al (1996) High-density mapping of chromosomal arm 1q in renal collecting duct carcinoma; region of minimal deletion at 1q32.1-32.2. Cancer Res 56:5044-5046
43. Polascik TJ, Bostwick DG, Cairns P (2002) Molecular genetics and histopathologic features of adult distal nephron tumors. Urology 60:941-946
44. Fuhrman SA, Lasky LC, Limas A (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655-663
45. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A (2000) Prognostic indicators for renal cell carcinoma: A multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 163:1090-1095
46. Delong W, Grignon DJ, Eberwein P et al (1993) Sarcomatoid renal cell carcinoma: An immunohistochemical study of 18 cases. Arch Pathol Lab Med 117:636-640
47. Voelzke B, Sakamoto K, Hantel A et al (2002) Gastointestinal stromal tumor: Involvement in urologic patients and recent therapeutic advances. Urology 60:218-222
48. Castillo M, Petit A, Mellado B et al (2004) C-kit expression in sarcomatoid renal cell carcinoma: Potential therapy with imatinib. J Urol 171:2176-2180
49. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade, and necrosis: The SSIGN scrore. J Urol 168:2395-2400
50. Lineham WM, Grubb RL, Coleman JA et al (2005) The genetic basis of kidney cancer: Implications for gene-specific clinical management BJU Int 95(suppl 2):2-7
51. Kim W, Kaelin WG Jr (2003) The von Hippel-Lindau tumor suppressor protein: New insights into oxygen sensing and cancer. Curr Opin Genet Dev 13:55
52. Gimenez-Bachs JM, Salinas-Sanchez AS, Sanchez-Sanchez T et al (2006) Determination of the VHL gene mutations in sporadic renal cell carcinoma. Eur Urol 49:1051
53. Motzer RJ, Rini BI, Bukowski RM et al (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516-2524
54. Atkins MB, Hidalgo M, Stadler W et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909-918
55. Amato RJ, Jac J (2006) Targeted anti-cancer therapies for renal cancer. Drugs 66:2161-2171
56. Duh FM, Scherer SW, Tsui LC et al (1997) Gene structure of the human MET proto-oncogene. Oncogene 15:1583-1586
57. Boccacio C, Comoglio PM (2006) Invasive growth: A MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6:637-645
58. Schmidt L, Duh FM, Chen F et al (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET prot-oncogene in papillary renal carcinomas. Nat Genet 16:68-73
59. Christensen JG, Schreck R, Burrows J et al (2003) A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 63:7345-7355
60. Sattler M, Pride YB, Ma P et al (2003) A novel small molecule me inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 63:5462-5469
61. Burgess T, Coxon A, Meyer S (2006) Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 66:1721-1729
62. Launonen V, Vierumaa O, Liuru M et al (2001) Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci USA 98:3387-3392
63. Alam NA, Olpin S, Leigh IM (2005) Fumarate hydratase mutations and predisposition to cutaneous leiomyomas, uterine leiomyomas and renal cancer. Br J Dermatol 153:11-17
64. Isaacs JS, Jung YJ, Mole DR et al (2005) HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability. Cancer Cell 8:143-153
65. Zbar B, Alvord WG, Glenn G et al (2002) Risk of renal and colonic nepoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. Cancer Epidemiol Biomarkers Prev 11:393-400
66. Toro JR, Glenn G, Duray P et al (1999) Birt-Hogg-Dube syndrome: A novel marker of kidney neoplasia. Arch Dermatol 135:1195-1202
67. Khoo SK, Bradley M, Wong FK et al (2001) Birt-Hogg-Dube syndrome: mapping of a novel hereditary neoplasia to chromosome 17p12-q11.2. Oncogene 20:5239-5242
68. Vocke CD, Yang Y, Pavlovich CP et al (2005) High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dube-associated renal tumors. J Natl Cancer Inst 97:931-935
69. Pavlovich CP, Walther MM, Eyler RA et al (2002) Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol 26:1542-1552
70. Lindgren V, Paner GP, Flanigan RC, Clark JI, Campbell SC, Picken MM (2004) Renal tumor with overlapping distal nephron morphology and karyotype. Arch Pathol Lab Med 128:1274-1278
71. Lindgren V, Paner GP, Omeroglu A, Campbell SC et al (2004) Cytogenetic analysis of a series of 13 renal oncoytomas. J Urol 171:602-604
72. Meyer PN, Clark JI, Flanigan RC, Picken MM (2007) Xp11.2 translocation r enal cell carcinoma with very aggressive course in five adults. Am J Clin Path 128:70-79
73. Argani P, Olgac S, Tickoo SK et al (2007) Xp11 translocation renal cell carcinoma in adults: Expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol 21:1149-1160
74. Bui MH, Seligson D, Han KR et al (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 9:802-811
75. Kim HL, Seligson D, Liu X et al (2004) Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 10:5464-5471
76. Volpe A, Kachura J, Geddie WR, Evans AJ et al (2007) Techniques, safety, and accuracy of sampling renal tumors by fine needle aspiration and core biopsy. J Urol 178:379-386
77. Masoom S, Venkataraman G, Jensen J, Flanigan R, Wojcik EM (2007) Fine needle aspiration (FNA) of the kidney remains as useful adjunctive modality: Concordance of cytologic typing/grading with histology in 31 renal masses. Cytopathology (in press)
78. Barocas DA, Mathew S, DelPizzo JJ et al (2006) Renal cell carcinoma sub-typing by histopathology and fluorescence in situ hydridization on a needle-biopsy specimen. BJU Int 99:290-295